Apellis Pharmaceuticals, Inc.
http://www.apellis.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Apellis Pharmaceuticals, Inc.
Astellas CStO Pearson: We’re Not Short Of Opportunities To Compensate For LOEs
Astellas’ chief strategy officer, Adam Pearson, talks to Scrip about the company’s launch execution thrust for key therapies ahead of the loss of exclusivity for Xtandi and also deal-making appetite and choices, including the Iveric Bio buyout and walking away from the collaboration with Cartesian Therapeutics.
Abingworth Adds Stakes To Gilead’s Trodelvy Gamble
The venture capital firm is putting $210m into NSCLC trials for the antibody drug conjugate – with an opportunity in patients who fail on first line immunotherapy the most likely target.
Two Avian Flu Vaccines Among 10 New Products To Get EMA Nod
The European Medicines Agency has OKd two new H5N1 jabs, including a pandemic preparedness vaccine intended for use only if a flu pandemic is declared. Eight other products are also heading for EU-wide approval.
Crovalimab Gets First Nod In China For PNH, Fiercer Global Competition Awaits
The anti-C5 inhibitor sets an example of swift global trial and approval in China while fiercer competition awaits in the US, Europe and Japan.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice